Australian guidelines for the clinical care of people with COVID-19 - drug treatments not recommended outside of clinical trials

Published by Australian National Clinical Evidence Taskforce on Jun 13, 2023

View

Disclaimer

The consortium is seeking NHMRC approval of the guideline under section 14A of the National Health and Medical Research Council Act 1992. As part of the approval process (and for the lifetime of the guidelines), public consultation is required. We welcome your feedback and suggestions. Comments can be submitted via the feedback function under each recommendation in Magic or by emailing guidelines@covid19evidence.net.au.

These clinical guidelines are a general guide to appropriate practice, to be followed subject to the clinician’s judgement and the patient’s preference in each individual case. The guidelines are not intended to be proscriptive. They are designed to provide information to assist decision making and have been informed by the highest quality evidence available at the time of compilation. Accordingly, the parties involved in the development of these guidelines shall have no liability to any users of the information contained in this publication for any loss or damage, cost or expense incurred or arising from reliance on the information contained in this publication.  

Sponsors

Development of the Australian guidelines for the clinical care of people with COVID-19 is funded by the Australian Government Department of Health, Victorian Government Department of Health and Human Services, the Ian Potter Foundation and the Walter Cottman Endowment Fund, managed by Equity Trustees

Contact

Abstract

Language

en-au

PICOS

PICO 10.1

Population
Patients with COVID-19
Intervention
Anakinra
Comparator
Standard care
Outcomes

PICO 10.1

Population
Patients with COVID-19
Intervention
Human umbilical cord mesenchymal stem cells (hUC-MSC)
Comparator
Standard care
Outcomes

PICO 10.1

Population
Patients with COVID-19
Intervention
Inhaled interferon β-1a
Comparator
Standard care
Outcomes

PICO 10.1

Population
Patients with COVID-19
Intervention
C21
Comparator
Placebo
Outcomes

PICO 10.1

Population
Patients with COVID-19
Intervention
Dutasteride
Comparator
Standard Care
Outcomes

PICO 10.1

Population
Patients with COVID-19
Intervention
Bamlanivimab
Comparator
Standard care
Outcomes

PICO 10.1

Population
Special populations with COVID-19
Intervention
Chloroquine
Comparator
Standard care
Outcomes

PICO 10.1

Population
Patients with COVID-19
Intervention
Almitrine
Comparator
Placebo
Outcomes

PICO 10.1

Population
Children or adolescents outpatients with mild or asymptomatic COVID-19
Intervention
Casirivimab plus imdevimab
Comparator
Placebo
Outcomes

PICO 10.1

Population
Special Populations with COVID-19
Intervention
Baricitinib
Comparator
Standard care
Outcomes

PICO 10.1

Population
Special populations with COVID-19
Intervention
Telmisartan
Comparator
Standard care
Outcomes

PICO 10.1

Population
Patients with COVID-19
Intervention
Baloxavir marboxil
Comparator
Standard care
Outcomes

PICO 10.1

Population
Sulodexide for COVID-19
Intervention
Sulodexide
Comparator
Placebo
Outcomes

PICO 10.1

Population
Patients with COVID-19
Intervention
Combined metabolic activators
Comparator
Control
Outcomes

PICO 10.2

Population
Patients with COVID-19
Intervention
Telmisartan
Comparator
Standard care
Outcomes

PICO 10.2

Population
Special populations with COVID-19
Intervention
Baloxavir marboxil
Comparator
Standard care
Outcomes

PICO 10.2

Population
Patients with COVID-19
Intervention
Chloroquine
Comparator
Standard care
Outcomes

PICO 10.2

Population
Evusheld for COVID-19 prophylaxis
Intervention
Evusheld
Comparator
placebo - treatment
Outcomes

PICO 10.3

Population
Evusheld for COVID-19 prophylaxis
Intervention
Evusheld
Comparator
placebo - treatment
Outcomes

PICO 10.4

Population
Evusheldvac for COVID-19
Intervention
Evusheld
Comparator
Placebo
Outcomes

PICO 20.1

Population
Special populations with mild or moderate COVID-19
Intervention
Sotrovimab
Comparator
Placebo
Outcomes

PICO 20.1

Population
Patients with COVID-19
Intervention
N-acetylcysteine
Comparator
Placebo
Outcomes

PICO 20.1

Population
Patients with COVID-19
Intervention
Aprepitant
Comparator
Standard care
Outcomes

PICO 20.1

Population
Patients with COVID-19
Intervention
Bamlanivimab plus etesevimab
Comparator
Placebo
Outcomes

PICO 20.1

Population
Special populations with COVID-19
Intervention
Molnupiravir
Comparator
Placebo
Outcomes

PICO 20.1

Population
Special populations with COVID-19
Intervention
Interferon β-1b
Comparator
Standard care
Outcomes

PICO 20.1

Population
Patients with COVID-19
Intervention
CD24Fc
Comparator
Placebo
Outcomes

PICO 20.1

Population
Patients with COVID-19
Intervention
Camostat mesilate
Comparator
Placebo
Outcomes

PICO 20.1

Population
Patients with COVID-19
Intervention
Immunoglobulin
Comparator
Control
Outcomes

PICO 20.1

Population
Patients with COVID-19
Intervention
Doxycycline
Comparator
Standard care
Outcomes

PICO 20.1

Population
Special populations with COVID-19
Intervention
Darunavir-cobicistat
Comparator
Standard care
Outcomes

PICO 20.2

Population
Special populations with COVID-19
Intervention
Aprepitant
Comparator
Standard care
Outcomes

PICO 20.2

Population
Darunavir-cobicistat for COVID-19
Intervention
Darunavir-cobicistat
Comparator
Standard care
Outcomes

PICO 20.2

Population
Patients with COVID-19
Intervention
Interferon β-1b
Comparator
Standard care
Outcomes

PICO 30.1

Population
Patients with COVID-19
Intervention
Vitamin C
Comparator
Standard care
Outcomes

PICO 30.1

Population
Special populations with COVID-19
Intervention
Interferon gamma
Comparator
Standard care
Outcomes

PICO 30.1

Population
Patients with COVID-19
Intervention
Ivermectin plus doxycycline
Comparator
Standard care
Outcomes

PICO 30.1

Population
People with COVID-19 (not requiring oxygen)
Intervention
Regdanvimab
Comparator
Placebo
Outcomes

PICO 30.1

Population
Patients with Covid-19
Intervention
Opaganib
Comparator
Placebo
Outcomes

PICO 30.1

Population
OLD Patients with COVID-19
Intervention
Nirmatrelvir plus ritonavir
Comparator
Placebo
Outcomes

PICO 30.1

Population
Patients with COVID-19
Intervention
Enisamium
Comparator
Placebo
Outcomes

PICO 30.1

Population
Patients with COVID-19
Intervention
Bebtelovimab
Comparator
Placebo
Outcomes

PICO 30.1

Population
Patients with COVID-19
Intervention
Lenzilumab
Comparator
Placebo
Outcomes

PICO 30.1

Population
Patients with COVID-19
Intervention
Immunoglobulin plus methylprednisolone
Comparator
Standard care
Outcomes

PICO 30.1

Population
Patients with COVID-19
Intervention
Bromhexine
Comparator
SOC
Outcomes

PICO 30.2

Population
Special populations with COVID-19
Intervention
Immunoglobulin plus methylprednisolone
Comparator
Standard care
Outcomes

PICO 30.2

Population
Patients with COVID-19
Intervention
Interferon gamma
Comparator
Standard care
Outcomes

PICO 40.1

Population
Patients with COVID-19
Intervention
Vitamin D analogues
Comparator
Standard care
Outcomes

PICO 40.1

Population
Patients with COVID-19
Intervention
Nitazoxanide
Comparator
Standard care
Outcomes

PICO 40.1

Population
People with COVID-19 (not requiring oxygen)
Intervention
Regdanvimab
Comparator
Placebo
Outcomes

PICO 40.1

Population
Patients with COVID-19
Intervention
Fluvoxamine
Comparator
Placebo
Outcomes

PICO 40.1

Population
Special populations with COVID-19
Intervention
Ruxolitinib
Comparator
Placebo
Outcomes

PICO 40.1

Population
Patients with Covid-19
Intervention
Ensovibep
Comparator
Placebo
Outcomes

PICO 40.1

Population
Patients with COVID-19
Intervention
IFN-κ plus TFF2
Comparator
Standard care
Outcomes

PICO 40.1

Population
Patients with COVID-19
Intervention
Sarilumab
Comparator
Standard care
Outcomes

PICO 40.2

Population
Patients with COVID-19
Intervention
Ruxolitinib
Comparator
Placebo
Outcomes

PICO 50.1

Population
Patients with COVID-19
Intervention
Sarilumab
Comparator
Standard care
Outcomes

PICO 50.1

Population
Patients with COVID-19
Intervention
Zinc
Comparator
Standard care
Outcomes

PICO 50.1

Population
Patients with COVID-19
Intervention
Metformin
Comparator
Placebo
Outcomes

PICO 50.1

Population
Patients with COVID-19
Intervention
Tofacitinib
Comparator
Placebo
Outcomes

PICO 50.1

Population
Patients with COVID-19
Intervention
Peginterferon lambda
Comparator
Standard care
Outcomes

PICO 50.1

Population
Patients with COVID-19
Intervention
Sofosbuvir-daclatasvir
Comparator
Standard care
Outcomes

PICO 50.2

Population
Patients with COVID-19 NEW
Intervention
Peginterferon lambda
Comparator
Standard care
Outcomes

PICO 60.1

Population
Paxlovid for hospitalised COVID-19
Intervention
Paxlovid
Comparator
Standard care
Outcomes

PICO 60.1

Population
Patients with COVID-19
Intervention
rhG-CSF
Comparator
Standard care
Outcomes

PICO 60.1

Population
Patients with COVID-19
Intervention
Triazavirin
Comparator
Placebo
Outcomes

PICO 60.2

Population
Special populations with COVID-19
Intervention
rhG-CSF
Comparator
Standard care
Outcomes

PICO 70.1

Population
Sabizabulin for COVID-19
Intervention
Sabizabulin
Comparator
Placebo
Outcomes

PICO 70.1

Population
Patients with COVID-19
Intervention
Umifenovir
Comparator
Standard care
Outcomes